Up next

Global Briefs: Lupin & Sanofi 

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Lupin and Sanofi. Highlights below.  

For the latest news roundup on small and Emerging Pharma companies, see Biotech Briefs. 

Partnering News 
* Lupin Spins Out Two Oncology Programs, Takes Equity Stake in Kaveri Therapeutics 
Appointments 
* Sanofi Announces Leadership Changes

Partnering News 

Lupin Spins Out Two Oncology Programs; Takes Equity Stake in Kaveri Therapeutics 
Lupin has announced the strategic spin-out of two oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), two drugs for treating solid tumors, through its wholly owned subsidiary, Lupin Inc., into Kaveri Therapeutics, a clinical-stage oncology company. Kaveri will advance these programs through global clinical trials. 

Under the agreement, Lupin Inc. will take an undisclosed equity stake in Kaveri, provide seed funding to the company, and grant Kaveri exclusive rights to the programs. Kaveri will seek to raise additional capital to fund its clinical development efforts. Kaveri’s pipeline includes programs targeting the PRMT5 and SOS1/RAS-pathway biology, with an initial development focus in solid tumors, including lung, pancreatic, ovarian, and central nervous system-relevant cancers. 

Source: Lupin 

Appointments 

Sanofi Announces Leadership Changes 
Sanofi has announced a series of changes to its Executive Committee. The changes come following Belén Garijo, formerly Chair and CEO of Merck KGaA, taking the helm as CEO of Sanofi in late April (April 2026). In late June (June 2026), Sanofi named Paulo Fontoura, an ex-Roche executive and formerly Chief Medical Officer at Xaira Therapeutics, a South San Francisco, California-based company focused on applying AI and machine learning in drug discovery and development, as Executive Vice President, Global Head of Research & Development Pharma, effective September 1, 2026.  

Now, the next set of changes has been announced, and effective September 1, 2026, Sanofi’s Executive Committee will comprise: 

  • François Roger, Executive Vice President, Finance 
  • Paulo Fontoura, Executive Vice President, Head of Research & Development 
  • Manuela Buxo, Executive Vice President, Specialty Care 
  • Thomas Triomphe, Executive Vice President, Vaccines 
  • Thomas Grenier, Executive Vice President, General Medicines 
  • Brendan O’Callaghan, Executive Vice President, Manufacturing & Supply 
  • Jamie Haney, Executive Vice President, General Counsel 
  • Véronique Jaillet, Executive Vice President, Chief People Officer, ad interim 

Alongside the Executive Committee changes, Sanofi has also announced some changes within the company: 

  • Madeleine Roach, currently Head of Business Operations, will become President and Country Lead of Sanofi Germany, Switzerland and Austria.  
  • Thomas Triomphe will also assume responsibility for China, alongside his role as Executive Vice President, Vaccines. 
  • Olivier Charmeil, currently Executive Vice President, General Medicines, will transition to Strategic Projects Advisor to the CEO. 

Source: Sanofi